SCHEMBL2821641

SCHEMBL2821641

CCc1nc2ccc(F)c(Cl)c2c(OC(=O)OC)c1C

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
KDM4E B2RXH2 1/20 0.35
GAA P10253 1/20 0.34
FABP3 P05413 1/20 0.32
FABP4 P15090 1/20 0.32
FABP5 Q01469 1/20 0.32
MAPT P10636 2/20 0.32
TDP1 Q9NUW8 1/20 0.32
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32
PTGFR P43088 3/20 0.31
SLC10A2 Q12908 1/20 0.31
EGFR P00533 1/20 0.31
CYP3A4 P08684 1/20 0.31
BRAF P15056 1/20 0.31
NPSR1 Q6W5P4 2/20 0.31
PIK3CD O00329 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2824342 0.91 ALDH1A1 (0.34) ALDH1A1L3MBTL1KDM4EGAAFABP3
SCHEMBL2819546 0.90 KDM4E (0.31) ALDH1A1L3MBTL1KDM4EGAAFABP3
SCHEMBL2822078 0.88 MMP13 (0.37) ALDH1A1L3MBTL1KDM4EGAAMAPT
SCHEMBL2820332 0.88 FABP3 (0.33) ALDH1A1L3MBTL1KDM4EGAAFABP3
SCHEMBL2821878 0.86 ELANE (0.33) ALDH1A1L3MBTL1KDM4ETDP1NPC1
SCHEMBL2823475 0.83 USP2 (0.36) ALDH1A1L3MBTL1KDM4EGAAFABP3
SCHEMBL2851123 0.79 KDM4E (0.34) ALDH1A1L3MBTL1KDM4EGAAMAPT
SCHEMBL2819552 0.78 KDM4E (0.32) ALDH1A1L3MBTL1KDM4EGAAMAPT
SCHEMBL2820995 0.78 KDM4E (0.32) ALDH1A1L3MBTL1KDM4EGAAMAPT
SCHEMBL2826725 0.76 FABP3 (0.33) L3MBTL1KDM4EGAAFABP3FABP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1386914-B1 HALOGENATED QUINOLINE DERIVATIVES AND ECTOPARASITE CONTROLLERS MEIJI SEIKA KAISHA (JP) 2010-10-27 EP disclosed
US-7022855-B2 Halogen-substituted quinoline derivatives and ectoparasite control agent MEIJI SEIKA KAISHA, LTD. (JP) 2006-04-04 US disclosed
EP-1559321-A1 MIXED COMPOSITIONS FOR CONTROLLING PARASITIC INSECTS MEIJI SEIKA KAISHA LTD. (JP) 2005-08-03 EP disclosed
US-20040087618-A1 Halogen-substituted quinoline derivatives and ectoparasite control agent MEIJI SEIKA KAISHA, LTD. (JP) 2004-05-06 US disclosed
US-20040077602-A1 Mixture composition for controlling ectoparasites MEIJI SEIKA KAISHA, LTD. (JP) 2004-04-22 US disclosed
EP-1386914-A1 HALOGENATED QUINOLINE DERIVATIVES AND ECTOPARASITE CONTROLLERS MEIJI SEIKA KAISHA LTD. (JP) 2004-02-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040087618-A1 Halogen-substituted quinoline derivatives and ectoparasite control agent ATL3, RABL3, RAB5C ALDH1A1 2123/4885L3MBTL1 130/4885KDM4E 2031/4885
US-20040077602-A1 Mixture composition for controlling ectoparasites SF3A3, PEX3, HCN3 ALDH1A1 3278/4885L3MBTL1 156/4885KDM4E 1688/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.